Western sanctions disrupted Russia’s access to imported medical devices, drugs, and biotech equipment. In response, Russia is scaling domestic pharma production and telehealth services to maintain healthcare access.
State-backed programs fund e-health platforms connecting rural clinics with urban specialists via telemedicine. Local pharma companies like Pharmstandard and R-Pharm ramp up generic drug manufacturing to reduce import reliance.
International collaborations shift toward Asian partners for vaccine research, clinical trials, and digital health tools.
